Galderma Group AG
F:PY30
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Galderma Group AG
F:PY30
|
CH |
|
A
|
Aurubis AG
DUS:NDA
|
DE |
|
S
|
Sinopharm Group Co Ltd
XMUN:X2S
|
CN |
|
Delta Electronics Thailand PCL
SET:DELTA
|
TH |
|
U
|
United Microelectronics Corp
F:UMCB
|
TW |
|
S
|
Schlumberger NV
XMUN:SCL
|
US |
Wall St Price Targets
PY30 Price Targets Summary
Galderma Group AG
According to Wall Street analysts, the average 1-year price target for PY30 is 40.61 EUR with a low forecast of 30.65 EUR and a high forecast of 54.95 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PY30's stock price target?
Price Target
40.61
EUR
According to Wall Street analysts, the average 1-year price target for PY30 is 40.61 EUR with a low forecast of 30.65 EUR and a high forecast of 54.95 EUR.
What is the Revenue forecast for Galderma Group AG?
Projected CAGR
13%
Over the last 3 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 8 years is 13%.
What is the Gross Profit forecast for Galderma Group AG?
Projected CAGR
15%
Over the last 3 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 8 years is 15%.
What is the Operating Income forecast for Galderma Group AG?
Projected CAGR
20%
Over the last 3 years, the compound annual growth rate for Operating Income has been 30%. The projected CAGR for the next 8 years is 20%.
What is the Pre-Tax Income forecast for Galderma Group AG?
Projected CAGR
57%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 57%.
What is the Net Income forecast for Galderma Group AG?
Projected CAGR
28%
The compound annual growth rate for Net Income over the next 8 years is 28%.
